Search Results for "this compound"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for this compound. Results 51 to 60 of 100 total matches.

Zolmitriptan for Migraine

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 1998  (Issue 1021)
mainly in urine. The half-life of the parent compound and its active N-desmethyl metabolite is about ...
Zolmitriptan (Zomig - Zeneca), a selective serotonin (5-HT1)-receptor agonist, is now available in the USA for oral treatment of migraine headache. Zomitriptan structurally resembles sumatriptan (Imitrex - Medical Letter 34:91, 1992). Drugs currently used for acute treatment of migraine include injectable, oral and nasal spray formulations of sumaptriptan, injectable dihydroergotamine, dihydroergotamine nasal spray, ergotamine tartrate alone or with caffeine, and various analgesics. Anoterh 5-HT1-receptor agonist, naratriptan (Amerge - Gaxo Wellcome), has been approved by the FDA but has not...
Med Lett Drugs Ther. 1998 Feb 27;40(1021):27-8 |  Show IntroductionHide Introduction

Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016  (Issue 1491)
CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation ...
The FDA has approved a fixed-dose combination of lumacaftor and ivacaftor (Orkambi – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who are homozygous for the F508del mutation. About 50% of patients in the US with CF are homozygous for the F508del (also called Phe508del) mutation. This is the first approved indication for lumacaftor; ivacaftor is available alone as Kalydeco for treatment of CF in patients ≥2 years old with other mutations. Orkambi is the first drug to be approved in the US for treatment of patients with the F508del...
Med Lett Drugs Ther. 2016 Mar 28;58(1491):41-2 |  Show IntroductionHide Introduction

Trospium (Sanctura): Another Anticholinergic for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004  (Issue 1188)
— Trospium is a quaternary ammonium compound that acts mainly as a muscarinic-receptor antagonist. Only ...
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
Med Lett Drugs Ther. 2004 Aug 2;46(1188):63-4 |  Show IntroductionHide Introduction

Acetylcysteine (Acetadote) for Acetaminophen Overdosage

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005  (Issue 1215)
compound, is thought to act by facilitating hepatic glutathione synthesis or by acting as an alternate ...
Acetaminophen (paracetamol; Tylenol, and others) taken in overdosage can cause severe hepatic injury and death. Acetaminophen poisoning is treated with (N-)acetylcysteine. Available for many years in the US as a solution for inhalation therapy (Mucomyst, and others), it subsequently became available for oral use and was recently marketed in the US for intravenous (IV) use as Acetadote (Cumberland).
Med Lett Drugs Ther. 2005 Aug 15;47(1215):70-1 |  Show IntroductionHide Introduction

Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia

   
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006  (Issue 1228)
al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory ...
Nelarabine (Arranon - GlaxoSmithKline), a prodrug of the deoxyguanosine analog 9-β-D-arabinofuranosylguanine (ara-G), has been approved by the FDA for treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.
Med Lett Drugs Ther. 2006 Feb 13;48(1228):14-5 |  Show IntroductionHide Introduction

Lisinopril For Hypertension

   
The Medical Letter on Drugs and Therapeutics • Apr 08, 1988  (Issue 763)
to form an active compound; peak serum concentrations are reached in about seven hours with lisinopril ...
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors, captopril (Capoten - Squibb) and e
Med Lett Drugs Ther. 1988 Apr 8;30(763):41-2 |  Show IntroductionHide Introduction

Ganciclovir

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 1989  (Issue 799)
triphosphate, the active antiviral compound. Ganciclovir triphosphate competes with deoxyguanosine triphosphate ...
Ganciclovir sodium (Cytovene - Syntex), a synthetic antiviral nucleoside analog, is now available in the USA for intravenous treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. CMV retinitis occurs in 20% to 25% of patients with AIDS.
Med Lett Drugs Ther. 1989 Aug 25;31(799):79-80 |  Show IntroductionHide Introduction

Treatment of Nerve Gas Poisoning

   
The Medical Letter on Drugs and Therapeutics • May 12, 1995  (Issue 948)
OF ACTION — Nerve agents are organophosphorous compounds, similar to but much more potent than ...
The recent attack in the Tokyo subway has led to many questions about the clinical effects, treatment and prevention of nerve gas poisoning.
Med Lett Drugs Ther. 1995 May 12;37(948):43-4 |  Show IntroductionHide Introduction

Cerivastatin for Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 1998  (Issue 1018)
predominantly to the parent compound. The metabolites are excreted in stool and, to a lesser extent, in urine ...
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.
Med Lett Drugs Ther. 1998 Jan 16;40(1018):13-4 |  Show IntroductionHide Introduction

Fenoldopam--A New Drug for Parenteral Treatment of Severe Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 22, 1998  (Issue 1027)
metabolized in the liver into inactive compounds that are excreted mainly in urine. The plasma elimination ...
Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA1) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral antihypertensive agents, fenoldopam not only lowers blood pressure but also maintains or improves renal function.
Med Lett Drugs Ther. 1998 May 22;40(1027):57-8 |  Show IntroductionHide Introduction